Efficacy of rituximab versus tacrolimus in difficult-to-treat steroid-sensitive nephrotic syndrome: an open-label pilot randomized controlled trial

Georgie Mathew(Christian Medical College, Vellore), Arvind Bagga(All India Institute of Medical Sciences), Aijaz Ahmed(Stanford University), Aditi Sinha, Neetu Grewal(All India Institute of Medical Sciences), Pankaj Hari(Indian Council of Medical Research), Priyanka Khandelwal(Chacha Nehru Bal Chikitsalaya)
Pediatric Nephrology
March 14, 2022
10.1007/s00467-022-05475-8
Cited by 21

Related Papers

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
|The Lancet|2019|1.2k
Patients with Mutations in NPHS2 (Podocin) Do Not Respond to Standard Steroid Treatment of Nephrotic Syndrome
|Journal of the American Society of Nephrology|2004|415
Clinical Features of Anti-Factor H Autoantibody–Associated Hemolytic Uremic Syndrome
|Journal of the American Society of Nephrology|2010|296
IPNA clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndrome
|Pediatric Nephrology|2022|256
Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children
|Kidney International|2013|216